Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicenter Trial of MB-CART2019.1 (Zamtocabtagene Autoleucel) Therapy as Frontline Consolidation for High-Risk Mantle Cell Lymphoma

NCT07569965 is registered in ClinicalTrials.gov with Miltenyi Biomedicine GmbH as lead sponsor.

NCT NCT07569965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07569965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicenter Trial of MB-CART2019.1 (Zamtocabtagene Autoleucel) Therapy as Frontline Consolidation for High-Risk Mantle Cell Lymphoma
Lead sponsor
Miltenyi Biomedicine GmbH
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
March 31, 2030
Enrollment
52 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma (mcl)